News & Announcements

Biased Estimates of New Drug Costs Miss by Billions

PHAR announced today the final results of a study, published in Current Medical Research and Opinion, which found that pre-launch predictions of the budget impact of newly developed drugs tended to be considerable overestimates of their actual sales. The study examined the accuracy of 25 publicly released predictions for the cost of drugs launched in… read more

bioTheranostics’ CancerTYPE ID® Molecular Test Is a Cost-Effective Approach to Standardizing Diagnosis & Improving Metastatic Cancer Care

A study completed by PHAR and researchers at bioTheranostics Inc found that use of bioTheranostics’ CancerTYPE ID® molecular test is a cost-effective approach to standardizing diagnostic methods for patients with metastatic tumors of uncertain origin while improving patient care. The study was the first of its kind to examine the implications of molecular classification in… read more